Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Pharmacia & Upjohn

Executive Summary

Pharmacia & Upjohn: Reorganization of R&D will more tightly focus resources on defined steps of product development, with three areas of "functional focus": preclinical, clinical and product development. The company recently began centralizing its global pharmaceutical business ("The Pink Sheet" July 7, p. 5). As part of the reorganization, five R&D executives are appointed to new duties. Former Pharma Product Center Sweden VP-Research Les Hudson, PhD, 53, is named divisional senior VP-worldwide discovery research. Per Olof Andersson, MD/PhD, 44, previously VP-development at the U.S. Pharma Product Center, will be divisional senior VP-exploratory development; his U.S. PPC colleague, former VP and Project Leader for Development John Landis, PhD, 44, is appointed divisional senior VP-preclinical development. Former Senior VP-Worldwide Product Development Birgit Stattin, 48, is named corporate senior VP-product development. Mike Tansey, MD/PhD, 49, will continue as chief medical officer and will add the title of divisional senior VP-clinical development...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel